WO2014137869A1 - Hepatitis c virus inhibitors - Google Patents

Hepatitis c virus inhibitors Download PDF

Info

Publication number
WO2014137869A1
WO2014137869A1 PCT/US2014/019810 US2014019810W WO2014137869A1 WO 2014137869 A1 WO2014137869 A1 WO 2014137869A1 US 2014019810 W US2014019810 W US 2014019810W WO 2014137869 A1 WO2014137869 A1 WO 2014137869A1
Authority
WO
WIPO (PCT)
Prior art keywords
methoxymethyl
carbamate
carbamoyl
dioxo
diazacyclopentadecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/019810
Other languages
English (en)
French (fr)
Inventor
Pulicharla NAGALAKSHMI
Kandhasamy SARKUNAM
Kishore V. Renduchintala
Paul Michael Scola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to CN201480025053.7A priority Critical patent/CN105164148A/zh
Priority to US14/768,229 priority patent/US9580463B2/en
Priority to EP14715470.2A priority patent/EP2964664B1/en
Priority to JP2015561490A priority patent/JP6342922B2/ja
Publication of WO2014137869A1 publication Critical patent/WO2014137869A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides

Definitions

  • the present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as "serine protease") encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.
  • NS3 protease also referred to herein as "serine protease”
  • HCV Hepatitis C virus
  • HCV is a major human pathogen, infecting an estimated 170 million persons worldwide - roughly five times the number infected by human immunodeficiency virus type 1. A substantial fraction of these HCV infected individuals develop serious progressive liver disease, including cirrhosis and hepatocellular carcinoma.
  • HCV is a positive-stranded RNA virus. Based on a comparison of the deduced amino acid sequence and the extensive similarity in the 5 ' untranslated region, HCV has been classified as a separate genus in the Flaviviridae family. All members of the Flaviviridae family have enveloped virions that contain a positive stranded RNA genome encoding all known virus-specific proteins via translation of a single, uninterrupted, open reading frame.
  • HCV RNA genome is approximately 9500 nucleotides in length and has a single open reading frame (ORF) encoding a single large polyprotein of about 3000 amino acids. In infected cells, this polyprotein is cleaved at multiple sites by cellular and viral proteases to produce the structural and non- structural (NS) proteins.
  • ORF open reading frame
  • the generation of mature non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) is effected by two viral proteases. The first one cleaves at the NS2-NS3 junction; the second one is a serine protease contained within the N-terminal region of NS3 and mediates all the subsequent cleavages downstream of NS3, both in cis, at the NS3-NS4A cleavage site, and in trans, for the remaining NS4A- NS4B, NS4B-NS5A, NS5A-NS5B sites.
  • the NS4A protein appears to serve multiple functions, acting as a co-factor for the NS3 protease and possibly assisting in the membrane localization of NS3 and other viral replicase components.
  • the complex formation of the NS3 protein with NS4A is essential for efficient polyprotein processing, enhancing the proteolytic cleavage at all of the sites.
  • the NS3 protein also exhibits nucleoside triphosphatase and RNA helicase activities.
  • NS5B is a RNA-dependent RNA polymerase that is involved in the replication of HCV.
  • the present disclosure provides peptide compounds that can inhibit the functioning of the NS3 protease, e.g., in combination with the NS4A protease.
  • the present disclosure describes the administration of combination therapy to a patient whereby a compound in accordance with the present disclosure, which is effective to inhibit the HCV NS3 protease, can be administered with additional compounds having anti-HCV activity.
  • p 1 or 2;
  • n 0, 1, or 2;
  • R 1 is attached to the parent molecular moiety through any substitutable carbon atom in the group
  • n 0, 1, 2, 3, 4, 5, or 6;
  • o 0, 1, 2, 3, 4, or 5;
  • q 0, 1, 2, 3, or 4;
  • X° is selected from CH and N;
  • X 1 is selected from CH and N;
  • X 2 and X 3 are independently selected from CH, C(R a ) and N; provided that at least one of X 1 , X 2 , and X 3 is other than N;
  • X 4 is selected from CH and CR a ;
  • one of X 5 , X 6 , X 7 , and X 8 is N and the others are selected from CH and CR a ;
  • X 9 is selected from CR a , CH, and N;
  • each R a is independently selected from alkenyloxy, alkoxy, alkoxyalkoxy, alkoxycarbonyl, alkyl, benzodioxanyl, carboxamido, carboxy, carboxyalkoxy, cyano, cycloalkyl, cycloalkylalkoxy, cycloalkyloxy, deuteroalkoxy, dialkylamino, halo, haloalkyl, haloalkoxy, haloalkoxycarbonyl, hydroxy, imidazolyl, morpholinyl, oxazolyl, phenyl, piperazinyl, pyrazolyl, pyridinyl, pyrrolidinyl, thiazolyl, and - NR q R q , wherein the imidazolyl, the morpholinyl, the oxazolyl, the phenyl, the piperazinyl, the pyridinyl, the pyrrolidiny
  • R b is alkyl
  • R x is selected from hydrogen and methyl
  • R 2 is selected from hydrogen, alkyl, deuteroalkyl, halo, haloalkoxy, haloalkyl, and hydroxyalkyl;
  • R 3 is selected from hydrogen, alkoxyalkoxycarbonyl, alkoxycarbonyl, alkylaminocarbonyl, alkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylcarbonyl, cycloalkyloxycarbonyl, deuteroalkoxycarbonyl, deuterohaloalkoxycarbonyl, dialkylaminocarbonyl, dialkylaminocarbonylcarbonyl, haloalkoxycarbonyl, haloalkylaminocarbonyl, haloalkylcarbonyl, heterocyclylcarbonyl,
  • heterocyclyloxycarbonyl, phenylcarbonyl, and phenyloxycarbonyl wherein the cycloalkyl part of the cycloalkylalkoxycarbonyl, the cycloalkylcarbonyl, and the cycloalkyloxycarbonyl, the heterocyclyl part of the heterocyclylcarbonyl and the heterocyclyloxycarbonyl, and the phenyl part of the phenylcarbonyl and the phenyloxycarbonyl, is optionally substituted with one , two, or three groups independently selected from alkyl, alkylamino, alkylcarbonyl, cycloalkyl, dialkylamino, halo, haloalkoxy, and haloalkyl; and
  • R q and R q is selected from hydrogen and alkyl and the other is selected from alkylcarbonyl and phenylcarbonyl.
  • the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein p is
  • R 1 is attached to the parent molecular moiety through any substitutable carbon atom in the group
  • n 1,
  • q 0, 1, 2, 3, or 4;
  • X° is selected from CH and N;
  • X 1 is selected from CH and N;
  • X 2 and X 3 are independently selected from CH, C(R a ) and N; provided that at least one of X 1 , X 2 , and X 3 is other than N;
  • X 4 is selected from CH and CR a ;
  • each R a is independently selected from alkoxy, alkyl, halo, and haloalkyl.
  • the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from hydrogen, alkyl, and haloalkyl.
  • the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from alkoxycarbonyl and haloalkoxycarbonyl.
  • the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein p is l;
  • n 1 ;
  • R 1 is attached to the parent molecular moiety through any substitutable carbon atom in the group; n is 1,
  • q 0, 1, 2, 3, or 4;
  • X° is selected from CH and N;
  • X 1 is selected from CH and N;
  • X 2 and X 3 are independently selected from CH, C(R a ) and N; provided that at least one of X 1 , X 2 , and X 3 is other than N;
  • X 4 is selected from CH and CR a ;
  • each R a is independently selected from alkoxy, alkyl, halo, and haloalkyl.
  • the present disclosure provides a composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, at least one additional compound having anti-HCV activity, and a pharmaceutical carrier.
  • at least one of the additional compounds is an interferon or a ribavirin.
  • the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau.
  • the present disclosure provides a composition
  • a composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, at least one additional compound having anti-HCV activity, and a pharmaceutical carrier, wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, Imiquimod, ribavirin, an inosine 5 '-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.
  • the present disclosure provides a composition
  • a composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, at least one additional compound having anti-HCV activity, and a pharmaceutical carrier, wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection.
  • a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection.
  • the present disclosure provides a method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • the method further comprises administering at least one additional compound having anti-HCV activity prior to, after, or simultaneously with the compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • at least one of the additional compounds is an interferon or a ribavirin.
  • the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau.
  • the present disclosure provides a method of treating an HCV infection in a patient, comprising administering to the patient a
  • a compound of formula (I), or a pharmaceutically acceptable salt thereof and at least one additional compound having anti-HCV activity prior to, after, or simultaneously with the compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, Imiquimod, ribavirin, an inosine 5 '-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.
  • the present disclosure provides a method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and at least one additional compound having anti-HCV activity prior to, after, or simultaneously with the compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection.
  • a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection
  • any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule.
  • n is 2
  • each of the two R 1 groups may be the same or different.
  • alkenyl refers to a group derived from a straight or branched chain saturated hydrocarbon containing from two to ten carbon atoms and at least one double bond. In one embodiment the alkenyl groups contain from two to six carbon atoms. In another embodiment the alkenyl groups contain from two to four carbon atoms.
  • alkenyloxy refers to an alkenyl group attached to the parent molecular moiety through an oxygen atom.
  • alkoxy refers to an alkyl group attached to the parent molecular moiety through an oxygen atom.
  • alkoxyalkoxy refers to an alkoxyalkyl group attached to the parent molecular moiety through an oxygen atom.
  • alkoxyalkoxycarbonyl refers to an alkoxyalkoxy group attached to the parent molecular moiety through a carbonyl group.
  • alkoxyalkyl refers to an alkyl group substituted with one, two, or three alkoxy groups.
  • alkoxycarbonyl refers to an alkoxy group attached to the parent molecular moiety through a carbonyl group.
  • alkyl refers to a group derived from a straight or branched chain saturated hydrocarbon containing from one to ten carbon atoms. In one embodiment the alkyl groups contain from one to six carbon atoms. In another embodiment the alkyl groups contain from one to four carbon atoms.
  • alkylamino refers to -NHR, wherein R is an alkyl group.
  • alkylaminocarbonyl refers to an alkylamino group attached to the parent molecular moiety through a carbonyl group.
  • alkylcarbonyl refers to an alkyl group attached to the parent molecular moiety through a carbonyl group.
  • alkylsulfonyl refers to an alkyl group attached to the parent molecular moiety through a sulfonyl group.
  • carbonyl refers to -C(O)-.
  • carboxylate refers to -C(0)NR x R y , wherein R and R y are independently selected from hydrogen and alkyl.
  • carboxyalkoxy refers to a carboxyalkyl group attached to the parent molecular moiety through an oxygen atom.
  • carboxyalkyl refers to an alkyl group substituted with one, two, or three carboxy groups.
  • cyano refers to -CN.
  • cycloalkyl refers to a saturated monocyclic or bicyclic hydrocarbon ring system having three to seven carbon atoms and zero heteroatoms.
  • Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, and cyclopentyl.
  • cycloalkylalkoxy refers to a (cycloalkyl)alkyl group attached to the parent molecular moiety through an oxygen atom.
  • cycloalkylalkoxycarbonyl refers to a
  • cycloalkylalkoxy group attached to the parent molecular moiety through a carbonyl group.
  • (cycloalkyl)alkyl refers to an alkyl group substituted with one, two, or three cycloalkyl groups.
  • cycloalkylcarbonyl refers to a cycloalkyl group attached to the parent molecular moiety through a carbonyl group.
  • cycloalkyloxy refers to a cycloalkyl group attached to the parent molecular moiety through an oxygen atom.
  • cycloalkyloxycarbonyl refers to a cycloalkyloxy group attached to the parent molecular moiety through a carbonyl group.
  • deuteroalkoxy refers to an alkoxy group wherein at least one hydrogen atom is replaced by a deuterium atom.
  • deuteroalkoxycarbonyl refers to a deuteroalkoxy group attached to the parent molecular moiety through a carbonyl group.
  • deuteroalkyl refers to an alkyl group wherein at least one hydrogen atom is replaced by a deuterium atom.
  • deuterohaloalkoxy refers to a haloalkoxy group wherein at least one hydrogen atom is replaced by a deuterium atom.
  • deuterohaloalkoxycarbonyl refers to a
  • deuterohaloalkoxy group attached to the parent molecular moiety through a carbonyl group.
  • dialkylamino refers to -NR p R q , wherein R p and R q are alkyl groups.
  • the alkyl groups may be the same or different.
  • dialkylaminocarbonyl refers to a dialkylamino group attached to the parent molecular moiety through a carbonyl group.
  • dialkylaminocarbonylcarbonyl refers to a dialkylaminocarbonyl group attached to the parent molecular moiety through a carbonyl group.
  • haloalkoxy refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.
  • haloalkoxycarbonyl refers to a haloalkoxy group attached to the parent molecular moiety through a carbonyl group.
  • haloalkyl refers to an alkyl group substituted with one, two, three, or four halogen atoms.
  • haloalkylamino refers to an alkyl amino group wherein the alkyl is substituted with one, two, three, or four halogen atoms.
  • haloalkylaminocarbonyl refers to a
  • haloalkylamino group attached to the parent molecular moiety through a carbonyl group.
  • haloalkylcarbonyl refers to a haloalkyl group attached to the parent molecular moiety through a carbonyl group.
  • heterocyclyl refers to a four-, five-, six-, or seven- membered ring containing one, two, three, or four heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • the four-membered ring has zero double bonds, the five-membered ring has zero to two double bonds, and the six- and seven- membered rings have zero to three double bonds.
  • heterocyclyl also includes bicyclic groups in which the heterocyclyl ring is fused to another monocyclic heterocyclyl group, or a four- to six-membered aromatic or non-aromatic carbocyclic ring; as well as bridged bicyclic groups such as 7-azabicyclo[2.2.1]hept- 7-yl, 2-azabicyclo[2.2.2]oc-2-tyl, and 2-azabicyclo[2.2.2]oc-3-tyl.
  • the heterocyclyl groups of the present disclosure can be attached to the parent molecular moiety through any carbon atom or nitrogen atom in the group.
  • heterocyclyl groups include, but are not limited to, benzothienyl, furyl, imidazolyl, indolinyl, indolyl, isothiazolyl, isoxazolyl, morpholinyl, oxazolyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrrolopyridinyl, pyrrolyl, thiazolyl, thienyl, thiomorpholinyl, 7-azabicyclo[2.2.1]hept-7-yl, 2-azabicyclo[2.2.2]oc-2-tyl, and 2- azabicyclo[2.2.2]oc-3-tyl.
  • heterocyclylcarbonyl refers to a heterocyclyl group attached to the parent molecular moiety through a carbonyl group.
  • heterocyclyloxy refers to a heterocyclyl group attached to the parent molecular moiety through an oxygen atom.
  • heterocyclyloxycarbonyl refers to a
  • heterocyclyloxy group attached to the parent molecular moiety through a carbonyl group.
  • hydroxy refers to -OH.
  • hydroxyalkyl refers to an alkyl group substituted with one, two, or three hydroxy groups.
  • phenylcarbonyl refers to a phenyl group attached to the parent molecular moiety through a carbonyl group.
  • phenyloxy refers to a phenyl group attached to the parent molecular moiety through an oxygen atom.
  • phenyloxycarbonyl refers to a phenyloxy group attached to the parent molecular moiety through a carbonyl group.
  • sulfonyl refers to -S(0) 2 -.
  • the compounds of the present disclosure can exist as pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt represents salts or zwitterionic forms of the compounds of the present disclosure which are water or oil-soluble or dispersible, which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
  • the salts can be prepared during the final isolation and purification of the compounds or separately by reacting a suitable basic functionality with a suitable acid.
  • Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate,
  • camphorsulfonate digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2- hydroxyethanesulfonate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para- toluenesulfonate, and undecanoate.
  • acids which can be employed to form pharmaceutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfur
  • Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting an acidic group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • the cations of pharmaceutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N- methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, and N,N'-dibenzylethylenediamine.
  • nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethyl
  • representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
  • anti-HCV activity means the compound is effective to treat the HCV virus.
  • compounds of the disclosure and equivalent expressions, are meant to embrace compounds of formula (I), and pharmaceutically acceptable enantiomers, diastereomers, and salts thereof. Similarly, references to intermediates, are meant to embrace their salts where the context so permits.
  • patient includes both human and other mammals.
  • composition means a composition comprising a compound of the disclosure in combination with at least one additional
  • pharmaceutical carrier i.e., adjuvant, excipient or vehicle
  • adjuvant i.e., adjuvant, excipient or vehicle
  • preserving agents such as diluents, preserving agents, fillers, flow regulating agents, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms.
  • diluents i.e., preserving agents, fillers, flow regulating agents, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms.
  • diluents such as diluents, preserving agents, fillers, flow regulating agents, disintegrating
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable risk/benefit ratio.
  • terapéuticaally effective amount means the total amount of each active component that is sufficient to show a meaningful patient benefit, e.g., a sustained reduction in viral load.
  • a meaningful patient benefit e.g., a sustained reduction in viral load.
  • the term refers to that ingredient alone.
  • the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or
  • treat and “treating” refers to: (i) preventing a disease, disorder or condition from occurring in a patient which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it; (ii) inhibiting the disease, disorder or condition, i.e., arresting its development; and/or (iii) relieving the disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition.
  • the designations PI ', PI, P2, P2*, P3, and P4, as used herein, map the relative positions of the amino acid residues of a protease inhibitor binding relative to the binding of the natural peptide cleavage substrate. Cleavage occurs in the natural substrate between PI and PI ' where the nonprime positions designate amino acids starting from the C-terminus end of the peptide natural cleavage site extending towards the N-terminus; whereas, the prime positions emanate from the N-terminus end of the cleavage site designation and extend toward the C-terminus.
  • PI ' refers to the first position away from the right hand end of the C-terminus of the cleavage site (i.e. N-terminus first position); whereas PI starts the numbering from the left hand side of the C-terminus cleavage site, P2: second position from the C-terminus, etc.).
  • the compounds may include PI cyclopropyl element of formula
  • Ci and C 2 each represent an asymmetric carbon atom at positions 1 and 2 of the cyclopropyl ring.
  • R 2 is syn to carbonyl
  • R 2 is syn to carbonyl
  • R 2 is syn to amide
  • R 2 is syn to amide
  • Certain compounds of the present disclosure may also exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers.
  • the present disclosure includes each conformational isomer of these compounds and mixtures thereof.
  • Certain compounds of the present disclosure may exist in zwitterionic form and the present disclosure includes each zwitterionic form of these compounds and mixtures thereof.
  • compositions which include therapeutically effective amounts of compounds of formula (I) or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof are as described above.
  • the carrier(s), diluent(s), or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • a process for the preparation of a pharmaceutical formulation including admixing a compound of formula (I), or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Dosage levels of between about 0.01 and about 150 milligram per kilogram (“mg/kg”) body weight per day, preferably between about 0.05 and about 100 mg/kg body weight per day of the compounds of the disclosure are typical in a monotherapy for the prevention and treatment of HCV mediated disease. Typically, the pharmaceutical compositions of this disclosure will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • mg/kg milligram per kilogram
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending on the condition being treated, the severity of the condition, the time of administration, the route of administration, the rate of excretion of the compound employed, the duration of treatment, and the age, gender, weight, and condition of the patient.
  • Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.
  • treatment is initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
  • the compound is most desirably administered at a concentration level that will generally afford antivirally effective results without causing any harmful or deleterious side effects.
  • compositions of this disclosure comprise a combination of a compound of the disclosure and one or more additional therapeutic and/or prophylactic agent
  • both the compound and the additional agent can be present in a dose that is less than or equal to the dosage normally administered in a monotherapy regimen.
  • the compositions of this disclosure may be co-formulated with one or more additional therapeutic or prophylactic agents, for example, in the form of a monolithic and/or bi/multi-layer tablet or may be administered separately from the therapeutic or prophylactic agent(s).
  • compositions may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual, or transdermal), vaginal, or parenteral (including subcutaneous, intracutaneous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional, intravenous, or intradermal injections or infusions) route.
  • Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).
  • compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil emulsions.
  • the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
  • an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
  • Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing, and coloring agent can also be present.
  • Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths.
  • Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate, or solid polyethylene glycol can be added to the powder mixture before the filling operation.
  • a disintegrating or solubilizing agent such as agar-agar, calcium carbonate, or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium chloride, and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, betonite, xanthan gum, and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant, and pressing into tablets.
  • a powder mixture is prepared by mixing the compound, suitable comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelating, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or and absorption agent such as betonite, kaolin, or dicalcium phosphate.
  • the powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage, or solutions of cellulosic or polymeric materials and forcing through a screen.
  • the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules.
  • the granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc, or mineral oil.
  • the lubricated mixture is then compressed into tablets.
  • the compounds of the present disclosure can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps.
  • a clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material, and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.
  • Oral fluids such as solution, syrups, and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound.
  • Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic vehicle.
  • Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and
  • polyoxyethylene sorbitol ethers preservatives, fiavor additive such as peppermint oil or natural sweeteners, or saccharin or other artificial sweeteners, and the like can also be added.
  • dosage unit formulations for oral administration can be microencapsulated.
  • the formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax, or the like.
  • the compounds of formula (I), and pharmaceutically acceptable salts thereof can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
  • Liposomes can be formed from a variety of phopholipids, such as cholesterol, stearylamine, or phophatidylcho lines.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysme substituted with palitoyl residues.
  • the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and cross-linked or amphipathic block copolymers of hydrogels.
  • a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and cross-linked or amphipathic block copolymers of hydrogels.
  • compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
  • the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).
  • compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols, or oils.
  • the formulations are preferably applied as a topical ointment or cream.
  • the active ingredient may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in oil base.
  • compositions adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
  • compositions adapted for topical administration in the mouth include lozenges, pastilles, and mouth washes.
  • compositions adapted for rectal administration may be presented as suppositories or as enemas.
  • compositions adapted for nasal administration wherein the carrier is a solid include a course powder which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or nasal drops, include aqueous or oil solutions of the active ingredient.
  • Fine particle dusts or mists which may be generated by means of various types of metered, dose pressurized aerosols, nebulizers, or insufflators.
  • compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulations.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, and soutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
  • formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • Table 1 lists some illustrative examples of compounds that can be administered with the compounds of this disclosure.
  • the compounds of the disclosure can be administered with other anti-HCV activity compounds in combination therapy, either jointly or separately, or by combining the compounds into a composition.
  • the compounds of the disclosure may also be used as laboratory reagents.
  • Compounds may be instrumental in providing research tools for designing of viral replication assays, validation of animal assay systems and structural biology studies to further enhance knowledge of the HCV disease mechanisms. Further, the compounds of the present disclosure are useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition.
  • the compounds of this disclosure may also be used to treat or prevent viral contamination of materials and therefore reduce the risk of viral infection of laboratory or medical personnel or patients who come in contact with such materials, e.g., blood, tissue, surgical instruments and garments, laboratory instruments and garments, and blood collection or transfusion apparatuses and materials.
  • materials e.g., blood, tissue, surgical instruments and garments, laboratory instruments and garments, and blood collection or transfusion apparatuses and materials.
  • This disclosure is intended to encompass compounds having formula (I) when prepared by synthetic processes or by metabolic processes including those occurring in the human or animal body (in vivo) or processes occurring in vitro.
  • abbreviations used in the present application are well-known to those skilled in the art. Some of the abbreviations used are as follows: LAH for lithium aluminum hydride; MsCl for methanesulfonyl chloride; Ph for phenyl; THF for tetrahydrofuran; min for minutes; h or hr or hrs for hours; DCM for dichloromethane; Ts for toluenesulfonyl; DMAP for ⁇ , ⁇ -dimethylaminopyridine; tBuOK for potassium tert- butoxide; DMSO for ⁇ , ⁇ -dimethylsulfoxide; DIPEA for diisopropylethylamine; MeOH for methanol; r.t.
  • HATU 0-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium phosphate
  • DCE for 1 ,2-dichloroethane
  • TBME or MTBE for methyl tert-butyl ether
  • EtOAC or EtOAc for ethyl acetate
  • pTSA para-tolylsulfonic acid
  • BOC or Boc for tert-butoxycarbonyl
  • CDI 1,1-carbonyldiimidazole
  • DBU for 1,8- diazabicyclo[5.4.0]undec-7-ene
  • TMS for trimethylsilane
  • DPPA for 0-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium phosphate
  • DCE for 1 ,2-dichloroethane
  • TBME or MTBE for methyl tert-
  • Step 2 Preparation of Hex-5-en-2-yl methanesulfonate
  • a solution of Hex-5-en-2-ol (50 g crude, 500 mmole) in dichloromethane was added triethylamine (103 m 5 L, 750 mmol) at room temperature.
  • the reaction mass was cooled to 0 °C and to it was added a solution of methane sulfonyl chloride (50.4 mL, 650 mmol) in DCM over a period of 30 min.
  • the reaction mass was allowed to come to room temperature and stirred for 2 h.
  • Step 4 Preparation -l-methoxy-4-methyloct-7-en-2-ol
  • reaction mass was allowed to come to room temperature and was stirred overnight.
  • the reaction mass was quenched with saturated aq. ammonium chloride solution and extracted with diethyl ether (200 mL x 3). The combined organic layers were dried over anhydrous Na 2 S0 4 and
  • Step 6 Preparation of (3R)-ethyl 2-((diphenylmethylene)amino)-3-(methoxymethyl)- -methylnon-8-enoate
  • Step 8 Preparation of (3R)-ethyl 2-((tert-butoxycarbonyl) amino)-3- (methoxymethyl)-5-methylnon-8-enoate
  • Step 9 Preparation of (3R)-2-((tert-butoxycarbonyl) amino)-3-(methoxymethyl)-5- methylnon-8-enoic acid
  • Step 10 Preparation of (2S,4R)-methyl l-((2S,3R)-2-((tert-butoxycarbonyl)amino)- 3-(methoxymethyl)-5-methylnon-8-enoyl)-4-hydroxypyrrolidine-2-carboxylate
  • hexafluorophosphate HATU, 5.5 g, 14.5 mmol
  • (2S,4R)- methyl 4-hydroxypyrrolidine-2-carboxylate HC1 (2.65 g, 14.5 mmol)
  • (3R)-2-((tert- butoxycarbonyl)amino)-3-(methoxymethyl)-5-methylnon-8-enoic acid (4 g, 12.14 mmol)
  • DIPEA 6.4 mL, 36.4 mmol
  • the reaction was washed with IN HC1 and then brine solutions. The organics were dried with magnesium sulfate, filtered and concentrated under vacuum.
  • Step 11 Preparation of (2S,4R)-l-((2S,3R)-2-((tert-butoxycarbonyl)amino)-3- (methoxymethyl)-5-methylnon-8-enoyl)-4-hydroxypyrrolidine-2-carboxylic acid
  • Step 1 Preparation of tert-butyl ((2S,3R)-l-((2S,4R)-2-(((lR,2S)-l- ((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)-4- hydroxypyrrolidin-l-yl)-3-(methoxymethyl)-5-methyl-l-oxonon-8-en-2-yl)carbamate
  • HATU (0.62 g, 1.62 mmol) was added to a solution of (2S,4R)-l-((2S,3R)-2- ((tert-butoxycarbonyl)amino)-3-(methoxymethyl)-5-methylnon-8-enoyl)-4- hydroxypyrrolidine-2-carboxylic acid (0.6 g, 1.35 mmol), (lR,2S)-l-amino-N- (cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide (3.75 g, 1.62 mmol), and DIPEA (4.0 mL, 76 mmol) in DCM (25 mL).
  • the reaction mixture was stirred at rt for 16 h.
  • the mixture was washed with IN HCl and then brine solution.
  • the organic layer was collected, dried over sodium sulfate, and concentrated under vacuum.
  • the crude material was purified by silica gel chromatography using a gradient of 20-60% acetone in hexanes.
  • Step 2 Preparation of tert-butyl ((2R,6S,7R,13aS,14aR,16aS,Z)-14a- ((cyclopropylsulfonyl)carbamoyl)-2-hydroxy-7-(methoxymethyl)-9-methyl-5 ,16- dioxo-1,2,3,5,6,7,8,9,10,1 l,13a,14,14a,15, 16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecin-6-yl)carbamate
  • Step 1 Preparation of tert-butyl ((2S,3R)-l-((2S,4R)-4-hydroxy-2-(((lR,2S)-l-(((l- methylcyclopropyl)sulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)pyrrolidin-l- yl)-3-(methoxymethyl)-5 -methyl- 1 -oxonon-8-en-2-yl)carbamate
  • HATU 0.516 g, 1.35 mmol
  • the reaction mixture was stirred at rt for 16 h.
  • the mixture was washed with 1 N HCl, and then brine solution.
  • the organic layer was collected, dried over sodium sulfate, and concentrated under vacuum.
  • the crude material was purified by silica gel chromatography using a gradient of 20-60% acetone in hexanes.
  • Step 2 Preparation of tert-butyl ((2R,6S,7R,13aS,14aR,16aS,Z)-2-hydroxy-7- (methoxymethyl)-9-methyl- 14a-((( 1 -methylcyclopropyl)sulfonyl)carbamoyl)-5 ,16- dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15, 16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecin-6-yl)carbamate
  • Step 1 Preparation of tert-butyl ((2S,3R)-l-((2S,4R)-2-(((lR,2S)-l-(((l- (fluoromethyl)cyclopropyl)sulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)-4- hydroxypyrrolidin-l-yl)-3-(methoxymethyl)-5-methyl-l-oxonon-8-en-2-yl)carbamate
  • HATU (0.56 g, 1.46 mmol) was added to a solution of (2S,4R)-1-((2S,3R)- 2- ((tert-butoxycarbonyl)amino)-3,5-dimethylnon-8-enoyl)-4-hydroxypyrrolidine-2- carboxylic acid (0.5 g, 1.13 mmol), (lR,2S)-l-amino-N-((l- (fluoromethyl)cyclopropyl)sulfonyl)-2-vinylcyclopropanecarboxamide hydrochloride (0.445 g, 1.35 mmol), and DIPEA (0.6 mL, 3.3 mmol) in DCM (20 mL).
  • Step 2 Preparation of tert-butyl ((2R,6S,7R,13aS,14aR,16aS,Z)-14a-(((l- (fluoromethyl)cyclopropyl)sulfonyl)carbamoyl)-2-hydroxy-7-(methoxymethyl)-9- methyl-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15, 16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecin-6-yl)carbamate
  • reaction mass was allowed to come to room temperature and was stirred Overnight.
  • the reaction mass was quenched with saturated aq. ammonium chloride solution and extracted with diethyl ether (50 mL x 3). The combined organic layers were dried over anhydrous Na 2 S0 4 and
  • Step 7 Preparation of (2S,4R)-methyl l-((2S,3R)-2-((tert-butoxycarbonyl)amino)-3- (methoxymethyl)non-8-enoyl)-4-hydroxypyrrolidine-2-carboxylate
  • hexafluorophosphate (HATU, 4.22 g, 11.1 mmol) was added to a solution of (2S,4R)- methyl 4-hydroxypyrrolidine-2-carboxylate HC1 (2.0 g, 11.1 mmol), (3R)-2-((tert- butoxycarbonyl)amino)-3-(methoxymethyl)non-8-enoic acid (3.5 g, 11.1 mmol) and DIPEA (5.8 mL, 33.3 mmol) in DCM (50 mL) and stirred at RT for 16 h. The reaction was washed with IN HC1 and then brine solution. The organics were dried with magnesium sulfate, filtered and concentrated under vacuum.
  • Step 8 Preparation of (2S,4R)-l-((2S,3R)-2-((tert-butoxycarbonyl)amino)-3- (methoxymethyl)non-8-enoyl)-4-hydroxypyrrolidine-2-carboxylic acid
  • Step 1 Preparation of tert-butyl ((2S, 3R)-l-((2S,4R)-2-(((lR,2S)-l-
  • Step 2 Preparation of tert-butyl ((2R,6S,7R,13aS,14aR,16aS,Z)-14a- ((cyclopropylsulfonyl)carbamoyl)-2-hydroxy-7-(methoxymethyl)-5 , 16-dioxo- 1,2,3,5,6,7,8,9,10,1 l,13a,14, 14a, 15,16, 16a-hexadecahydrocyclopropa[e]pyrrolo[l, 2- a] [ 1 ,4]diazacyclopentadecin-6-yl)carbamate
  • Step 1 Preparation of tert-butyl ((2S,3R)-l-((2S,4R)-4-hydroxy-2-(((lR,2S)-l-(((l- methylcyclopropyl)sulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)pyrrolidin-l- yl)-3-(methox methyl)- 1 -oxonon-8-en-2-yl)carbamate
  • Step 1 Preparation of tert-butyl (l-(hydroxymethyl)cyclopropyl)sulfonylcarbamate
  • Formaldehyde gas was generated from para-formaldehyde (by heating at 180°C) and was purged in to the above reaction mass for 30 min at -30°C. The reaction was stirred at the same temperature for 1 h and then allowed to warm to room
  • Step 3 Preparation of l-(fluoromethyl)cyclopropane-l -sulfonamide
  • Step 5 Preparation of (lR,2S)-l-amino-N-(l-(fluoromethyl)cyclopropylsulfonyl)-2- vinylcyclopropanecarboxamide hydrochloride
  • Step 1 Preparation of tert-butyl cyclopropylsulfonylcarbamate
  • Step 3 Preparation of 1 -methylcyclopropane- 1 -sulfonamide
  • Step 1 Preparation of l-chloro-4-methoxyisoquinoline
  • Step 1 Preparation of (E)-3-(4-fluorophenyl) acryloyl azide
  • Step 1 Preparation of 6-methoxy-3-(trifluoromethyl)quinoxalin-2(lH)-one and 7- methoxy-3 -(trifluoromethyl)quinoxalin-2( 1 H)-one
  • Steps 2 and 3 Preparation of 2-chloro-6-methoxy-3-(trifluoromethyl)quinoxaline and 3-chloro-6-methoxy-2-(trifluoromethyl)quinoxaline
  • Step 1 Preparation of 3-isopropyl-6-methoxyquinoxalin-2(lH)-one and 3-isopropyl- 7-methoxyquinoxalin-2( 1 H)-one
  • Step 2 Preparation of 2-chloro-3-isopropyl-6-methoxyquinoxaline and 3-chloro-2- isopropyl-6-methoxyquinoxaline
  • reaction mixture was stirred at room temperature for 2 h.
  • the reaction mass was quenched with aqueous citric acid solution and extracted with ethyl acetate (50 mL x 3).
  • the combined organic layer was washed with water, brine solution, dried over anhydrous Na 2 S0 4 and evaporated under reduced pressure to get crude compound tert-butyl
  • reaction mixture was stirred at room temperature for 30 min.
  • the reaction mass was diluted with DCM and washed with water.
  • the organic layer was dried over anhydrous Na 2 S0 4 and evaporated under reduced pressure to get crude compound as diastereomer mixture.
  • the crude compound was purified by prep-HPLC to get compound 1008 (14 mg, 12%) and Compound 1009 (19 mg, 17%) as white solids.
  • Compound 1001 was prepared using the intermediates described herein and by following the general procedure described for the synthesis of Compound 1016.
  • Compound 1001 l,l,l-trifluoro-2-methylpropan-2-yl
  • Compound 1002 was prepared using the intermediates described herein and by following the general procedure described for the synthesis of Compound 1016.
  • Compound 1002 l , l ,l-trifluoro-2-methylpropan-2-yl
  • Compound 1003 tert-butyl ((2R,6S,7R,9R,13aS,14aR,16aS,Z)-14a- ((cyclopropylsulfonyl)carbamoyl)-2-((4-methoxyisoquinolin-l-yl)oxy)-7- (methoxymethyl)-9-methyl-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15, 16,16a- hexadecahydrocyclopropa[e]pyrrolo[ 1 ,2-a] [ 1 ,4]diazacyclopentadecin-6- yl)carbamate.
  • Compound 1007 was prepared using the intermediates described herein and by following the general procedure described for the synthesis of Compound 1010.
  • Compound 1007 tert-butyl ((2R,6S,7R,13aS,14aR,16aS,Z)-2-((4- methoxyisoquinolin- 1 -yl)oxy)-7-(methoxymethyl)- 14a-((( 1 - methylcyclopropyl)sulfony l)carbamoyl)-5 , 16-dioxo- l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[l,2- a][l,4]diazacyclopentadecin-6-yl)carbamate.
  • Compound 1008 tert-butyl ((2R,6S,7R,9S,13aS,14aR,16aS,Z)-14a- ((cyclopropylsulfonyl)carbamoyl)-2-((6-methoxyisoquinolin-l-yl)oxy)-7- (methoxymethyl)-9-methyl-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15, 16,16a- hexadecahydrocyclopropa[e]pyrrolo[ 1 ,2-a] [ 1 ,4]diazacyclopentadecin-6- yl)carbamate.
  • Compound 1020 was prepared using the intermediates described herein and by following the general procedure described for the synthesis of Compound 1010.
  • Compound 1020 tert-butyl ((2R,6S,7R,13aS,14aR,16aS,Z)-14a- ((cyclopropylsulfonyl)carbamoyl)-2-((7-methoxy-3-(trifluoromethyl)quinoxalin-2- yl)oxy)-7-(methoxymethyl)-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15, 16,16a- hexadecahydrocyclopropa[e]pyrrolo[ 1 ,2-a] [ 1 ,4]diazacyclopentadecin-6- yl)carbamate.
  • Compound 1021 was prepared using the intermediates described herein and by following the general procedure described for the synthesis of Compound 1016.
  • Compound 1021 1,1,1 -trifluoro-2-methylpropan-2-yl
  • Compound 1022 was prepared using the intermediates described herein and by following the general procedure described for the synthesis of Compound 1010.
  • Compound 1022 tert-butyl ((2R,6S,7R,13aS,14aR,16aS,Z)-14a- ((cyclopropylsulfonyl)carbamoyl)-2-((7-fluoro-6-methoxynaphthalen-l-yl)oxy)-7- (methoxymethyl)-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15, 16,16a- hexadecahydrocyclopropa[e]pyrrolo[ 1 ,2-a] [ 1 ,4]diazacyclopentadecin-6- yl)carbamate.
  • Compound 1023 was prepared using the intermediates described herein and by following the general procedure described for the synthesis of Compound 1016.
  • Compound 1023 l,l,l-trifluoro-2-methylpropan-2-yl
  • Compound 1024 tert-butyl ((2R,6S,7R,9S,13aS,14aR,16aS,Z)-14a-(((l- (fluoromethyl)cyclopropyl)sulfonyl)carbamoyl)-2-((3-isopropyl-7- methoxyquinoxalin-2-yl)oxy)-7-(methoxymethyl)-9-methyl-5 , 16-dioxo- l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[l,2- a][l,4]diazacyclopentadecin-6-yl)carbamate.
  • Compound 1025 tert-butyl ((2R,6S,7R,9R,13aS,14aR,16aS,Z)-14a-(((l- (fluoromethyl)cyclopropyl)sulfonyl)carbamoyl)-2-((3-isopropyl-7- methoxyquinoxalin-2-yl)oxy)-7-(methoxymethyl)-9-methyl-5 , 16-dioxo- l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[l,2- a][l,4]diazacyclopentadecin-6-yl)carbamate.
  • Compound 1026 was prepared using the intermediates described herein and by following the general procedure described for the synthesis of Compound 1010.
  • Compound 1026 tert-butyl ((2R,6S,7R,9R,13aS,14aR,16aS,Z)-14a- ((cyclopropylsulfonyl)carbamoyl)-2-((7-fluoro-6-methoxynaphthalen-l-yl)oxy)-7- (methoxymethyl)-9-methyl-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15, 16,16a- hexadecahydrocyclopropa[e]pyrrolo[ 1 ,2-a] [ 1 ,4]diazacyclopentadecin-6- yl)carbamate.
  • MS MS: MS m/z 802 (M + +l).
  • Compound 1030 tert-butyl ((2R,6S,7R,9R,13aS,14aR,16aS,Z)-2-((3-isopropyl-7- methoxyquinoxalin-2-yl)oxy)-7-(methoxymethyl)-9-methyl-14a-(((l- methylcyclopropyl)sulfony l)carbamoyl)-5 , 16-dioxo- l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[l,2- a][l,4]diazacyclopentadecin-6-yl)carbamate.
  • Compound 1043 was prepared using the intermediates described herein and by following the general procedure described for the synthesis of Compound 1016.
  • Compound 1043 l , l ,l-trifluoro-2-methylpropan-2-yl
  • Step 3 Step 1 : Preparation of 4-ethoxy-2-nitroaniline
  • the crude compound was purified by ISCO using 10-30% ethyl acetate in hexane as mobile phase to get 4-ethoxy-2-nitroaniline (3.0 g, 16.47 mmol, 50.8 % yield) as red color solid.
  • Step 3 Preparation of 6-ethoxy-3-(trifluoromethyl)quinoxalin-2(lH)-one and 7- ethoxy-3 -(trifluoromethyl)quinoxalin-2( 1 H)-one
  • Step 4 Preparation of 2-chloro-6-ethoxy-3-(trifluoromethyl)quinoxaline and 3- chloro-6-ethoxy-2-(trifluoromethyl)quinoxaline
  • Step 3 Preparation of 6-isopropoxy-3-(trifluoromethyl)quinoxalin-2(lH)-one and 7- isopropoxy-3 -(trifluoromethyl)quinoxalin-2( 1 H)-one
  • Step 3 Preparation of 7-fluoro-6-methoxy-3 -(trifluoromethyl)quinoxalin-2( 1 H)-one and 6-fluoro-7-methoxy-3 -(trifluoromethyl)quinoxalin-2( 1 H)-one
  • Step 4 Preparation of 2-chloro-7-fluoro-6-methoxy-3-(trifluoromethyl)quinoxaline and 2-chloro-6-fluoro-7-methoxy-3 -(trifluoromethyl)quinoxaline
  • Compound 1045 tert-butyl ((2R,6S,7R,9S,13aS,14aR,16aS,Z)-2-((6-fhioro-7- methoxy-3 -(trifluoromethyl)quinoxalin-2-yl)oxy)-7-(methoxymethyl)-9-methyl- 14a- ((( 1 -methylcyclopropyl)sulfonyl)carbamoyl)-5 , 16-dioxo- l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[l,2- a][l,4]diazacyclopentadecin-6-yl)carbamate.
  • Compound 1050 tert-butyl ((2R,6S,7R,9R,13aS,14aR,16aS,Z)-2-((7-ethoxy-3- (trifluoromethyl)quinoxalin-2-yl)oxy)-7-(methoxymethyl)-9-methyl- 14a-((( 1 - methylcyclopropyl)sulfony l)carbamoyl)-5 , 16-dioxo- l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[l,2- a][l,4]diazacyclopentadecin-6-yl)carbamate.
  • Compound 1051 and Compound 1052 were prepared using the intermediates described herein and by following the general procedure described for the synthesis of Compound 1016 using 3,3-difluoro-2-methylbutan-2-yl pyridin-2-yl carbonate instead of pyridin-2-yl (1,1,1 -trifluoro-2-methylpropan-2-yl) carbonate.
  • Compound 1051 3,3-difluoro-2-methylbutan-2-yl
  • Compound 1055 and Compound 1056 were prepared using the intermediates described herein and by following the general procedure described for the synthesis of Compound 1016 using 3,3-difluoro-2-methylbutan-2-yl pyridin-2-yl carbonate instead of pyridin-2-yl (l,l,l-trifluoro-2-methylpropan-2-yl) carbonate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2014/019810 2013-03-07 2014-03-03 Hepatitis c virus inhibitors Ceased WO2014137869A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201480025053.7A CN105164148A (zh) 2013-03-07 2014-03-03 丙型肝炎病毒抑制剂
US14/768,229 US9580463B2 (en) 2013-03-07 2014-03-03 Hepatitis C virus inhibitors
EP14715470.2A EP2964664B1 (en) 2013-03-07 2014-03-03 Hepatitis c virus inhibitors
JP2015561490A JP6342922B2 (ja) 2013-03-07 2014-03-03 C型肝炎ウイルス阻害剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361774136P 2013-03-07 2013-03-07
US61/774,136 2013-03-07

Publications (1)

Publication Number Publication Date
WO2014137869A1 true WO2014137869A1 (en) 2014-09-12

Family

ID=50439475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/019810 Ceased WO2014137869A1 (en) 2013-03-07 2014-03-03 Hepatitis c virus inhibitors

Country Status (5)

Country Link
US (1) US9580463B2 (cg-RX-API-DMAC7.html)
EP (1) EP2964664B1 (cg-RX-API-DMAC7.html)
JP (1) JP6342922B2 (cg-RX-API-DMAC7.html)
CN (1) CN105164148A (cg-RX-API-DMAC7.html)
WO (1) WO2014137869A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150190A2 (en) * 2010-05-26 2011-12-01 Anacor Pharmaceuticals, Inc. Hcv inhibitor compounds and methods of use thereof
WO2012040242A1 (en) * 2010-09-22 2012-03-29 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012173983A1 (en) * 2011-06-15 2012-12-20 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Family Cites Families (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475255A3 (en) 1990-09-12 1993-04-14 F. Hoffmann-La Roche Ag Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
MXPA03004299A (es) 2000-11-20 2004-02-12 Bristol Myers Squibb Co Inhibidores de tripeptido de hepatitis c.
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
AU2003248535A1 (en) 2002-05-20 2003-12-12 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
PL215228B1 (pl) 2002-05-20 2013-11-29 Bristol Myers Squibb Co Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
ES2315568T3 (es) 2002-05-20 2009-04-01 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CN1771050A (zh) 2003-02-07 2006-05-10 益安药业 丙型肝炎丝氨酸蛋白酶的大环抑制剂
JP4550824B2 (ja) 2003-03-05 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎抑制化合物
DE602004029866D1 (de) 2003-03-05 2010-12-16 Boehringer Ingelheim Pharma Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
RS20050741A (sr) 2003-04-02 2007-06-04 Boehringer Ingelheim International Gmbh., Farmaceutske kompozicije za inhibitore virusne proteaze hepatitisa c
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
WO2004093798A2 (en) 2003-04-18 2004-11-04 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
EP1673385B1 (en) 2003-09-22 2011-03-02 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
NZ546663A (en) 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MXPA06005683A (es) 2003-11-20 2006-12-14 Schering Corp Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c.
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
ES2336009T3 (es) 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
ES2338666T3 (es) 2004-03-15 2010-05-11 Boehringer Ingelheim International Gmbh Procedimiento para la preparacion de dipeptidos macrociclicos adecuados para el tratamiento de infecciones viricas de la hepatitis c.
EP1749007A2 (en) 2004-03-30 2007-02-07 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2006016930A2 (en) 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
JP4914348B2 (ja) 2004-06-28 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎インヒビターペプチド類似体
KR20070034119A (ko) 2004-07-16 2007-03-27 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
JP4914355B2 (ja) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎インヒビターペプチド類似体
MX2007002371A (es) 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
US7375218B2 (en) 2004-09-17 2008-05-20 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic HCV protease inhibitors
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
MX2007004783A (es) 2004-10-21 2007-05-11 Pfizer Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103172697A (zh) 2005-03-08 2013-06-26 贝林格尔.英格海姆国际有限公司 制备大环化合物的方法
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US20060276407A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
JP2008545748A (ja) 2005-06-02 2008-12-18 シェーリング コーポレイション C型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
WO2006130666A2 (en) 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
US7772178B2 (en) 2005-06-02 2010-08-10 Schering Corporation Pharmaceutical formulations and methods of treatment using the same
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
US20080200497A1 (en) 2005-07-20 2008-08-21 Bailey Murray D Hepatitis C Inhibitor Peptide Analogs
EP2305696A3 (en) 2005-07-25 2011-10-12 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
EP1919904B1 (en) 2005-07-29 2014-01-08 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
BRPI0614637A2 (pt) 2005-07-29 2011-04-12 Tibotec Pharm Ltd inibidores macrocìclicos do vìrus da hepatite c
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
AR055105A1 (es) 2005-07-29 2007-08-08 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de la hepatitis c
EP1910347A2 (en) 2005-07-29 2008-04-16 Medivir Ab Macrocylic inhibitors of hepatitis c virus
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
RU2436787C2 (ru) 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
ATE496042T1 (de) 2005-07-29 2011-02-15 Tibotec Pharm Ltd Makrocyclische inhibitoren des hepatitis-c-virus
WO2007014922A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
US8278322B2 (en) 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2007016476A2 (en) 2005-08-01 2007-02-08 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP1934243B1 (en) 2005-09-09 2011-05-25 Boehringer Ingelheim International GmbH Ring-closing metathesis process for the preparation of macrocyclic peptides
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2007082131A1 (en) 2006-01-09 2007-07-19 Bristol-Myers Squibb Company Process for the preparation of hydroxy substituted heterocycles
JP2009528353A (ja) 2006-03-03 2009-08-06 シェーリング コーポレイション Hcvのプロテアーゼ阻害剤およびires阻害剤の医薬的組み合わせ
WO2007120595A2 (en) 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US20070281884A1 (en) 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
UY30437A1 (es) 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US7893264B2 (en) 2006-07-07 2011-02-22 Gilead Sciences, Inc. Antiviral phosphinate compounds
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
ES2448494T3 (es) 2006-07-13 2014-03-14 Achillion Pharmaceuticals, Inc. Péptidos de 4-amino-4-oxobutanoilo en calidad de inhibidores de la replicación viral
CN101674844A (zh) 2006-08-04 2010-03-17 英安塔制药有限公司 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US20090035267A1 (en) 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
WO2008019303A2 (en) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
WO2008021960A2 (en) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis c serine protease inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US20080038225A1 (en) 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
US20090035268A1 (en) 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
WO2008022006A2 (en) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CN101583372A (zh) 2006-10-24 2009-11-18 默克公司 Hcv ns3蛋白酶抑制剂
CA2667165A1 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
WO2008057208A2 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP5268927B2 (ja) 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Hcvns3プロテアーゼ阻害剤
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107623A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US20080107625A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
WO2008057995A2 (en) 2006-11-02 2008-05-15 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (en) 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008059046A1 (en) 2006-11-17 2008-05-22 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
US20100323953A1 (en) 2007-01-08 2010-12-23 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
US20080207528A1 (en) 2007-02-01 2008-08-28 Syaulan Yang Hcv protease inhibitors
RU2483067C2 (ru) 2007-02-01 2013-05-27 Тиботек Фармасьютикалз Лтд. Способы и промежуточные продукты для получения макроциклического ингибитора протеазы вируса гепатита с
SI2118098T1 (sl) 2007-02-01 2015-01-30 Janssen R&D Ireland Polimorfne oblike makrocikličnega inhibitorja HCV
MX2009008541A (es) 2007-02-08 2009-08-18 Tibotec Pharm Ltd Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
RU2481340C2 (ru) 2007-02-08 2013-05-10 Тиботек Фармасьютикалз Лтд. Пиримидин-замещенные макроциклические ингибиторы hcv
WO2008096002A1 (en) 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates
JP2010518128A (ja) 2007-02-16 2010-05-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎ns3プロテアーゼのインヒビター
BRPI0807887A2 (pt) 2007-02-20 2014-06-17 Novartis Ag Compostos macrocíclicos como inibidores de hcv ns3 protease.
EP2125113A2 (en) 2007-02-26 2009-12-02 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
ES2355437T3 (es) 2007-04-24 2011-03-25 F. Hoffmann-La Roche Ag Procedimiento para un intermediario de inhibidores de proteasa del vhc.
US20080292587A1 (en) 2007-04-26 2008-11-27 Ying Sun Oximyl dipeptide hepatitis c protease inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
WO2008134395A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis c serine protease inhibitors
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
WO2008137779A2 (en) 2007-05-03 2008-11-13 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CA2686546A1 (en) 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
NZ582096A (en) 2007-06-29 2012-05-25 Gilead Sciences Inc Antiviral compounds that inhibit hepatitis c virus (hcv)
AR068794A1 (es) 2007-06-29 2009-12-09 Gilead Sciences Inc Compuestos antivirales
AR067180A1 (es) 2007-06-29 2009-09-30 Gilead Sciences Inc Compuestos antivirales
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
KR101396696B1 (ko) 2007-10-10 2014-05-16 노파르티스 아게 스피로피롤리딘, 및 hcv 및 hiv 감염에 대한 그의 용도
WO2009053828A2 (en) 2007-10-22 2009-04-30 Enanta Pharmaceuticals, Inc. P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
JP2011503201A (ja) 2007-11-14 2011-01-27 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状テトラゾリルc型肝炎セリンプロテアーゼ阻害剤
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8030307B2 (en) 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
CA2708150A1 (en) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide hcv serine protease inhibitors
MX2010006209A (es) 2007-12-05 2010-08-10 Enanta Pharm Inc Derivados de quinoxalinilo.
WO2009073713A1 (en) 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
WO2009076166A2 (en) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Oximyl hcv serine protease inhibitors
CA2708047A1 (en) 2007-12-06 2009-06-11 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis c protease inhibitors
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
JP2011506472A (ja) 2007-12-14 2011-03-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状オキシミルc型肝炎セリンプロテアーゼ阻害剤
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
CN104557880A (zh) 2007-12-21 2015-04-29 阿维拉制药公司 Hcv蛋白酶抑制剂和其用途
WO2009082697A1 (en) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
AU2008340430B2 (en) 2007-12-21 2013-01-24 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
JP2011510926A (ja) 2008-01-24 2011-04-07 エナンタ ファーマシューティカルズ インコーポレイテッド ヘテロアリール含有トリペプチドhcvセリンプロテアーゼ阻害剤
CA2713005A1 (en) 2008-01-24 2009-07-30 Enanta Pharmaceuticals, Inc. Difluorinated tripeptides as hcv serine protease inhibitors
CA2714604A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Macrocyclic hcv ns3 protease inhibitors
CA2719008A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
WO2009142842A2 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102014911A (zh) 2008-04-28 2011-04-13 默沙东公司 Hcv ns3蛋白酶抑制剂
WO2009134987A1 (en) 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
US20090285773A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102046648A (zh) 2008-05-29 2011-05-04 百时美施贵宝公司 丙型肝炎病毒抑制剂
ES2392611T3 (es) 2008-07-22 2012-12-12 Merck Sharp & Dohme Corp. Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC
EP2323981B1 (en) 2008-08-07 2014-03-12 F. Hoffmann-La Roche AG Process for the preparation of a macrocycle
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
TW201023858A (en) 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
WO2010031832A2 (en) 2008-09-18 2010-03-25 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
EP2344487A4 (en) 2008-09-23 2012-03-21 Boehringer Ingelheim Int HEPATITIS C INHIBITOR COMPOUNDS
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5689810B2 (ja) 2008-11-20 2015-03-25 アキリオン ファーマシューティカルズ,インコーポレーテッド C型肝炎ウイルス用の環状カルボキサミド化合物およびその類似体
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20100152103A1 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
ES2527166T3 (es) 2008-12-10 2015-01-21 Achillion Pharmaceuticals, Inc. Nuevos péptidos de 4-amino-4-oxobutanoílo como inhibidores de la replicación viral
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2011006631A (es) 2008-12-19 2011-09-06 Gilead Sciences Inc Inhibidores de proteasa ns3 del virus hcv.
AU2009330333A1 (en) 2008-12-22 2011-07-07 Gilead Sciences, Inc. Antiviral compounds
JP2012516351A (ja) 2009-01-30 2012-07-19 アナコール ファーマシューティカルズ,インコーポレーテッド 化合物
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
CA2761650C (en) 2009-05-13 2015-05-26 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
CN101921308A (zh) 2009-06-16 2010-12-22 上海唐润医药科技有限公司 具有抗hcv活性的化合物及其用途
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
PE20120322A1 (es) 2009-07-07 2012-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
EP2470189A4 (en) 2009-08-27 2013-01-23 Merck Sharp & Dohme METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS
EP2477980B1 (en) 2009-09-15 2016-06-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CN105001302A (zh) 2009-09-28 2015-10-28 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
MX2012003171A (es) 2009-09-28 2012-04-11 Hoffmann La Roche Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
TW201116540A (en) 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US9193740B2 (en) 2009-10-19 2015-11-24 Enanta Pharmaceuticals, Inc. Bismacrocyclic compounds as hepatitis C virus inhibitors
WO2011063502A1 (en) 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
JP2013511561A (ja) 2009-11-24 2013-04-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎阻害化合物
MX2012007076A (es) 2009-12-18 2012-07-20 Boehringer Ingelheim Int Terapia combinada de hcv.
CA2788155C (en) 2010-01-27 2018-04-24 AB Pharma Ltd. Polyheterocyclic compounds highly potent as hcv inhibitors
US20110312973A1 (en) 2010-03-10 2011-12-22 Bernd Liepold Solid compositions
EP2576564A4 (en) 2010-06-07 2014-01-22 Abbvie Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
WO2012019299A1 (en) 2010-08-11 2012-02-16 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2012037259A1 (en) 2010-09-15 2012-03-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
TWI523658B (zh) 2010-09-21 2016-03-01 安塔製藥公司 巨環脯胺酸衍生之hcv絲胺酸蛋白酶抑制劑
WO2012040040A1 (en) 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
WO2012047764A1 (en) 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
WO2012054874A1 (en) 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CN103717067A (zh) 2010-12-14 2014-04-09 默沙东公司 制备大环内酰胺的方法与中间体
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012166459A1 (en) 2011-05-27 2012-12-06 Bristol-Myers Squibb Company Tripeptides incorporating deuterium as inhibitors of hepatitis c virus
MX2014001945A (es) 2011-08-19 2014-03-27 Merck Sharp & Dohme Procedimiento e intermedios para la preparacion de macrolactamas.
JP2014530195A (ja) 2011-09-16 2014-11-17 アッヴィ・インコーポレイテッド Hcvを治療するための方法
WO2013066753A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Compositions useful for the treatment of viral diseases
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
US9040479B2 (en) 2012-01-12 2015-05-26 Cocrystal Pharma, Inc. HCV NS3 protease inhibitors
CN102617705B (zh) 2012-02-16 2014-12-31 上海纬诺医药科技有限公司 抑制丙肝病毒复制的大环类化合物
US20130302414A1 (en) 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
TW201408669A (zh) 2012-08-08 2014-03-01 Merck Sharp & Dohme Hcv ns3蛋白酶抑制劑
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C型肝炎ウイルス阻害剤
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150190A2 (en) * 2010-05-26 2011-12-01 Anacor Pharmaceuticals, Inc. Hcv inhibitor compounds and methods of use thereof
WO2012040242A1 (en) * 2010-09-22 2012-03-29 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012173983A1 (en) * 2011-06-15 2012-12-20 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1999, MACK PUBLISHING COMPANY
BERGER A.; SCHECHTER I., TRANSACTIONS OF THE ROYAL SOCIETY LONDON SERIES, vol. B257, 1970, pages 249 - 264
BLIGHT KJ; KOLYKHALOV, AA; RICE, CM, SCIENCE, vol. 290, no. 5498, pages 1972 - 1974
GALLINARI P; BRENNAN D; NARDI C; BRUNETTI M; TOMEI L; STEINKUHLER C; DE FRANCESCO R., J VIROL, vol. 72, no. 8, 1998, pages 6758 - 69
GALLINARI P; PAOLINI C; BRENNAN D; NARDI C; STEINKUHLER C; DE FRANCESCO R, BIOCHEMISTRY, vol. 38, no. 17, 1999, pages 5620 - 32
KRIEGER N; LOHMANN V; BARTENSCHLAGER R, J. VIROL., vol. 75, no. 10, 2001, pages 4614 - 4624
LOHMANN V; KORNER F; KOCH J; HERIAN U; THEILMANN L; BARTENSCHLAGER R., SCIENCE, vol. 285, no. 5424, 1999, pages 110 - 3
P SIMMONDS; KA ROSE; S GRAHAM; SW CHAN; F MCOMISH; BC DOW; EA FOLLETT; PL YAP; H MARSDEN, J. CLIN. MICROBIOL., vol. 3 1, no. 6, 1993, pages 1493 - 1503
PHARMACEUTICAL RESEARCH, vol. 3, no. 6, 1986, pages 318
TALIANI ET AL., ANAL. BIOCHEM., vol. 240, no. 2, 1996, pages 60 - 67
YANAGI M; PURCELL RH; EMERSON SU ET AL.: "Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee", PROC NATL ACAD SCI USA, vol. 94, no. 16, 1997, pages 8738 - 8743, XP002918288, DOI: doi:10.1073/pnas.94.16.8738
YANAGI,M.; PURCELL,R.H.; EMERSON,S.U.; BUKH, J, PROC. NATL. ACAD. SCI. US.A., vol. 94, no. 16, 1997, pages 8738 - 8743
YANAGI,M.; ST CLAIRE,M.; SHAPIRO,M.; EMERSON,S.U.; PURCELL,R.H.; BUKH, J., VIROLOGY, vol. 244, no. 1, 1998, pages 161 - 172

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
US20150376233A1 (en) 2015-12-31
JP2016517399A (ja) 2016-06-16
JP6342922B2 (ja) 2018-06-13
CN105164148A (zh) 2015-12-16
EP2964664B1 (en) 2017-01-11
EP2964664A1 (en) 2016-01-13
US9580463B2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
EP2300490B1 (en) Hepatitis c virus inhibitors
US8563505B2 (en) Hepatitis C virus inhibitors
US8283310B2 (en) Hepatitis C virus inhibitors
EP2049474B1 (en) Hepatitis c virus inhibitors
EP2265606B1 (en) Hepatitis c virus inhibitors
US8044023B2 (en) Hepatitis C virus inhibitors
EP2283018B1 (en) Hepatitis c virus inhibitors
EP2721053B1 (en) Hepatitis c virus inhibitors
US20090285774A1 (en) Hepatitis C Virus Inhibitors
EP2726475B1 (en) Tripeptides incorporating deuterium as inhibitors of hepatitis c virus
EP2705049A1 (en) Hepatitis c virus inhibitors
US9643999B2 (en) Hepatitis C virus inhibitors
EP2914614B1 (en) Hepatitis c virus inhibitors
EP2914598B1 (en) Hepatitis c virus inhibitors
EP2914613B1 (en) Hepatitis c virus inhibitors
EP2964664B1 (en) Hepatitis c virus inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480025053.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14715470

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2014715470

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14768229

Country of ref document: US

Ref document number: 2014715470

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015561490

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE